Share on StockTwits
 

Research analysts at Deutsche Bank raised their price target on shares of Chelsea Therapeutics International (NASDAQ:CHTP) to $8.00 in a report released on Wednesday, Stock Ratings Network reports. Deutsche Bank’s price objective would indicate a potential upside of 61.62% from the company’s current price.

A number of other firms have also recently commented on CHTP. Analysts at Needham & Company raised their price target on shares of Chelsea Therapeutics International to $10.00 in a research note on Wednesday. Separately, analysts at Roth Capital raised their price target on shares of Chelsea Therapeutics International to $7.00 in a research note on Friday, January 17th. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Chelsea Therapeutics International to $7.00 in a research note on Wednesday, January 15th. Three analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $8.00.

Shares of Chelsea Therapeutics International (NASDAQ:CHTP) opened at 4.95 on Wednesday. Chelsea Therapeutics International has a 52-week low of $1.17 and a 52-week high of $5.78. The stock’s 50-day moving average is $4.25 and its 200-day moving average is $3.46. The company’s market cap is $350.3 million. Chelsea Therapeutics International also was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 5,352,469 shares, a drop of 32.4% from the January 15th total of 7,912,013 shares. Based on an average daily volume of 5,243,831 shares, the short-interest ratio is presently 1.0 days. Currently, 7.4% of the shares of the company are sold short.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.